Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics (IBT) is a Swedish pharma company based in Stockholm dedicated to developing drugs influencing the infant gut microbiome to prevent or treat rare diseases affecting premature newborns. Lead candidate IBP-9414 (Lactobacillus reuteri) aims to prevent necrotizing enterocolitis and sepsis. Pipeline also includes IBP-1016 (gastroschisis), IBP-1118 (ROP) and IBP-1122 (antibiotic-resistant infections). Listed on Nasdaq First North.